BPC-157 without a baseline lab panel removes the ability to measure whether therapy is working or whether it is creating a problem. That is the single largest quality gap between well-run peptide practices and drive-by telehealth services in 2026.
Why BPC-157 Specifically Requires a Panel
BPC-157 is a 15-amino-acid peptide derived from gastric juice with well-documented effects on GI healing musculoskeletal tissue repair and systemic inflammation reduction. Three things about that mechanism profile make pre-treatment labs non-negotiable:
First BPC-157 promotes angiogenesis the growth of new blood vessels. This is desirable for tissue healing and undesirable in active cancer or recent cancer history. Reasonable oncology screening is part of responsible pre-treatment workup.
Second BPC-157 modulates systemic inflammation. If baseline inflammatory markers are elevated we need the starting number to measure whether the peptide is reducing it. Unmeasured baseline produces unmeasurable outcomes.
Third BPC-157 is most often used for gut indications. If gut environment has upstream problems SIBO dysbiosis elevated zonulin chronic infection BPC-157 works against a headwind that may dominate peptide effect. Measuring the gut environment first changes whether BPC-157 is right at all or whether it should come after gut-environment work.
The Pre-Treatment Panel
Core Metabolic and Inflammatory: CBC with differential. CMP with liver and kidney function. Fasting glucose HbA1c fasting insulin. Lipid panel. hs-CRP above 3.0 mg/L document starting number and expect it to fall. Above 10.0 mg/L stop and investigate underlying driver. ESR and fibrinogen as secondary inflammation markers. Ferritin as iron-status and acute-phase reactant.
Gut-Environment Markers (for gut indications): GI-MAP stool PCR for pathogen panel dysbiosis markers calprotectin secretory IgA. Elevated zonulin signals intestinal permeability we want BPC-157 to address. Chronic infection signals we want to address before BPC-157. SIBO breath test if clinical picture suggests small intestinal overgrowth.
Oncology Screening: CBC with differential. PSA for males. CA-125 for females. CA 19-9 symptom-driven. Active cancer history review. Recent age-appropriate cancer screening compliance.
Thyroid and Adrenal Baseline: TSH FT3 FT4 reverse T3. Morning cortisol with or without diurnal. Hypothyroid patients heal slowly; addressing thyroid first changes BPC-157 response.
Liver Detail: GGT for specificity. Direct plus indirect bilirubin. Alkaline phosphatase as hepatic and bone marker.
Nutrient Status: Vitamin D 25-OH sufficiency anchor. B12 plus MMA-corrected for neurologic and metabolic cofactor. Magnesium RBC for tissue magnesium status.
Monitoring During Protocol
Re-labs at mid-cycle and end-of-cycle. hs-CRP movement is the primary efficacy marker. Liver function and kidney function at 60 days. Repeat zonulin if gut-healing was the indication.
What This Panel Tells You
BPC-157 is a precision tool. The lab panel tells you whether precision is possible or whether upstream work comes first. A well-designed baseline is the difference between a clinical outcome and a blind experiment.
Work with Dr. Bright
Root-cause care combining Traditional Chinese Medicine pattern diagnosis with functional medicine testing — in person at the Tustin clinic or by virtual visit. Book a consultation.
Related reading
- How to Talk to Your Conventional Doctor About Your Functional Medicine Findings (Without the Conversation Going Sideways)
- Biological Age vs Chronological Age What Your Functional Labs Actually Reveal About How You are Aging 2026 DAOM Guide
- 10 Labs Your Conventional Doctor Won’t Order (But Should): A Functional Medicine Perspective
- Why Your Labs Are Normal But You Feel Terrible: The Functional Medicine Explanation